CD19 and systemic sclerosis: In a recent clinical trial, allogeneic anti-CD19 CAR-T cells with PDCD1 gene knockout achieved sustained B-cell depletion and drug-free remission for over six months in patients with myositis and systemic sclerosis, with no severe adverse events (89).